Frontier Pharma: Asthma – Identifying and Commercializing First-in-Class … – Medgadget.com (blog)


Medgadget.com (blog)

Frontier Pharma: Asthma – Identifying and Commercializing First-in-Class
Medgadget.com (blog)
Analysis has confirmed the asthma pipeline to be highly active, with 252 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing …

View full post on asthma – Google News

Frontier Pharma: Asthma – Identifying and Commercializing First-in-Class … – PR Newswire (press release)

Frontier Pharma: Asthma – Identifying and Commercializing First-in-Class
PR Newswire (press release)
Analysis has confirmed the asthma pipeline to be highly active, with 252 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing …

and more »

View full post on asthma – Google News

Research and Markets: Frontier Pharma: Asthma – Identifying and … – Business Wire (press release)

Research and Markets: Frontier Pharma: Asthma – Identifying and
Business Wire (press release)
Analysis has confirmed the asthma pipeline to be highly active, with 252 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing …

and more »

View full post on asthma – Google News

Asthma market to remain stable over next decade, despite generic erosion – The Pharma Letter


The Pharma Letter

Asthma market to remain stable over next decade, despite generic erosion
The Pharma Letter
New market potential in underserved asthma population: Emerging anticytokines that are predicted to launch during the next decade will serve part of the unmet need in the severe, refractory asthma population, which is currently served by only systemic …

View full post on asthma – Google News

Asthma’s treatment pipeline very strong as more personalized medicines emerge – The Pharma Letter

Asthma's treatment pipeline very strong as more personalized medicines emerge
The Pharma Letter
According to research and consulting firm GlobalData's latest report, the most significant challenge in asthma therapeutics is posed by patients with severe forms of the disease, who remain uncontrolled and have frequent exacerbations, even with the …

View full post on asthma – Google News

Global asthma market to hit $18 billion by 2021 boosted by biologics – The Pharma Letter


The Pharma Letter

Global asthma market to hit $18 billion by 2021 boosted by biologics
The Pharma Letter
Natasha Spiller, an analyst at Datamonitor Healthcare said: “Severe asthma remains a significant cause of mortality and morbidity and a portion of patients remain inadequately treated, despite the use of inhaled corticosteroids and long-acting beta 2

View full post on asthma – Google News

GSK and Theravance submit US sNDA for Breo Ellipta in asthma – The Pharma Letter


The Pharma Letter

GSK and Theravance submit US sNDA for Breo Ellipta in asthma
The Pharma Letter
Today's filing is based on data generated from the comprehensive clinical development program for FF/VI in asthma. The clinical development program comprised 48 clinical pharmacology studies in 1,328 subjects and 23 clinical studies in 12,051 patients …
Glaxo, Theravance File Asthma Drug Application with FDANASDAQ
Glaxo submits new drug application for asthma treatmentIFA Magazine
GSK and Theravance Announce Submission to US Regulatory Authorities for MarketWatch
RTT News
all 15 news articles »

View full post on asthma – Google News